Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

Inclusion Criteria: Multiple Myeloma Criteria(International Uniform Response Criteria for Multiple Myeloma) * Patients with responsive disease after any line of induction therapy * A complete response * A very good partial response * A partial response * Patients greater than or equal to 18 years of age are eligible. There is upper age limit of 60 years for allogeneic transplants. * Patients must have a histologically confirmed diagnosis. * All patients should have a life expectancy of at least 12 weeks. * Patients must have undergone a complete psychosocial evaluation and have been considered capable of compliance. * Meet the following criteria for allogeneic hematopoietic cell transplant: * Must have an identified donor match defined as: HLA-A, HLA-B, HLA- C, DRB1 8/8 allele matched sibling, family member, or unrelated donor. \[7/8 would go on separate mismatched trials\] and be \< 60 years of age. * Calculated hematopoietic cell transplantation-specific comorbidity index (HCT-CI) \<3 Exclusion Criteria: * Patients who do not achieve at least a partial response (PR) by the criteria mentioned above with induction therapy. * Patient has a platelet count of \<30 x 10\^9/L within 14 days before enrollment. * Patient has \>/= Grade 2 peripheral neuropathy within 30 days before enrollment. * Patient has an absolute neutrophil count of \<1.0 x 10\^9/L within 30 days before enrollment. * Myocardial infarction within 6 months prior to enrollment or has New York Hospital Associat…